P53- and mevalonate pathway–driven malignancies require Arf6 for metastasis and drug resistance

Drug resistance, metastasis, and a mesenchymal transcriptional program are central features of aggressive breast tumors. The GTPase Arf6, often overexpressed in tumors, is critical to promote epithelial–mesenchymal transition and invasiveness. The metabolic mevalonate pathway (MVP) is associated wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cell Biol
Autors principals: Hashimoto, Ari, Oikawa, Tsukasa, Hashimoto, Shigeru, Sugino, Hirokazu, Yoshikawa, Ayumu, Otsuka, Yutaro, Handa, Haruka, Onodera, Yasuhito, Nam, Jin-Min, Oneyama, Chitose, Okada, Masato, Fukuda, Mitsunori, Sabe, Hisataka
Format: Artigo
Idioma:Inglês
Publicat: The Rockefeller University Press 2016
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4828690/
https://ncbi.nlm.nih.gov/pubmed/27044891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1083/jcb.201510002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars